MGF vs MK-677 (Ibutamoren)
A neutral, side-by-side comparison of two performance & growth hormone peptides — their mechanisms, dosing ranges, administration routes, side effects, and research evidence. For research and educational purposes only.
MGF
MGF (Mechano Growth Factor) is a splice variant of IGF-1 produced locally in muscle tissue in response to mechanical loading (exercise, especially eccentric loading). Unlike circulating IGF-1 which is produced primarily by the liver, MGF is generated within the muscle itself and acts locally to activate satellite cells (muscle stem cells) — the cells responsible for muscle repair, growth, and adaptation. It is considered the primary local anabolic signal generated by resistance training.
Full profileMK-677 (Ibutamoren)
Oral non-peptide growth hormone secretagogue that mimics ghrelin to stimulate GH and IGF-1 release without injection. Long half-life (~24 hours) enables once-daily oral dosing. Widely researched for body composition, sleep quality, and IGF-1 elevation.
Full profile| MGF | MK-677 (Ibutamoren) | |
|---|---|---|
| Category | Performance & Growth Hormone | Performance & Growth Hormone |
| Also known as | Mechano Growth Factor, IGF-1Ec, Insulin-like Growth Factor splice variant | Ibutamoren, Nutrobal, MK677, L-163,191 |
| Evidence | Preclinical only | Research-stage |
| Dosing range | 100mcg–300mcg mcg, Post-workout (within 30–60 minutes of training), 3–4x weekly | 10mg–50mg mg, once daily oral |
| Administration | Intramuscular injection (into worked muscle — critical for local effect), Subcutaneous injection (produces more systemic distribution) | Oral (capsule/liquid) |
| Key side effects | Localized muscle swelling at injection site (normal response), Hypoglycemia (less pronounced than IGF-1 DES but present), Very short half-life means side effects are brief, Potential overuse injury if post-workout injection is used consistently without adequate recovery | Water retention, Increased appetite, Elevated fasting glucose (long-term), Fatigue (initial, transient) |
| Cited sources | 3 references | 2 references |
Key differences
- Evidence level differs: MGF is preclinical only, while MK-677 (Ibutamoren) is research-stage.
- Administration: MGF — Intramuscular injection (into worked muscle — critical for local effect), Subcutaneous injection (produces more systemic distribution); MK-677 (Ibutamoren) — Oral (capsule/liquid).
- Dosing units differ: MGF is dosed in mcg, MK-677 (Ibutamoren) in mg — they operate at different scales.
- Frequency: MGF is typically Post-workout (within 30–60 minutes of training), 3–4x weekly; MK-677 (Ibutamoren) is once daily oral.
- Research depth: this profile cites 3 sources for MGF vs 2 for MK-677 (Ibutamoren).
How each works
MGF
MGF is encoded by the IGF-1 gene but produced via alternative splicing that generates a unique 49-amino acid C-terminal E-peptide (Ec peptide). The Ec peptide has distinct biological activity from the IGF-1 domain — it directly activates satellite cell proliferation through a receptor pathway separate from the standard IGF-1R. Studies in rodents show that local MGF injection produces significant muscle hypertrophy in the injected limb without systemic IGF-1 elevation. MGF expression spikes within 30 minutes of resistance exercise and declines over 24–48 hours — aligning precisely with the post-exercise anabolic window.
MK-677 (Ibutamoren)
MK-677 binds the ghrelin receptor (GHS-R1a) to stimulate pulsatile GH release and increase circulating IGF-1. Unlike peptide GHRPs it survives oral administration. Clinical trials demonstrate significant increases in GH pulsatility and IGF-1 without suppression of the endogenous GH axis, though long-term use raises glucose metabolism concerns.
This comparison aggregates public research and structured profile data for informational purposes only. It is not medical advice and does not recommend either compound for human use. Consult a qualified healthcare provider before considering any peptide.